News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Astria Therapeutics
NEWS
JOBS
IN THE PRESS
NEWS
Business
BioSpace Movers & Shakers: Astria, Apertura, CytoDyn, IN8bio & More Make Big Moves
New leaders and top executive roles were selected to guide biopharma and life science companies from Apertura Gene Therapy to CytoDyn, Vaccentis AG, Suvoda LLC, IN8bio and more.
July 14, 2022
·
9 min read
·
Alex Keown
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress
February 20, 2025
·
2 min read
Press Releases
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 4, 2025
February 5, 2025
·
1 min read
Press Releases
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 4, 2025
·
1 min read
Press Releases
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session
February 3, 2025
·
1 min read
Press Releases
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
January 23, 2025
·
7 min read
Press Releases
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE
January 13, 2025
·
9 min read
Press Releases
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 3, 2025
January 6, 2025
·
1 min read
Press Releases
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
December 11, 2024
·
10 min read
Press Releases
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
December 10, 2024
·
6 min read
Press Releases
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 3, 2024
December 4, 2024
·
1 min read
